Keep up with our latest news, and connect with us on social media.


Epic Bio to Participate in the 6th International Conference on Epigenetics and Bioengineering 

SOUTH SAN FRANCISCO, Calif. — October 24, 2022 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022. 

ICEB 2022 Presentation Details: 

Poster Presentation Title: GEMS: A Platform for Transcriptional and Epigenome Engineering in Human Disease 

Session Name: Epigenetic Editing towards Clinic 

Presenter: Daniel Hart, Ph.D., Head of Technology Development 

Presentation Date/Time: October 29, 11:25 – 11:50 a.m. CT 

About Epic Bio 

Epic Bio is a leading epigenetic engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial hypercholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit for more information or follow us on Twitter and LinkedIn

Investor Contact 

Jessica Vo 

Gilmartin Group, LLC 

Media Contact 

Lisa Raffensperger 
Ten Bridge Communications 
(617) 903-8783 

The latest from Epic

16 Nov

"The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. Read more here: "

7 Nov

"We are pleased to share that Epic Bio CEO Dr. Amber Salzman has been invited to present at the 2023 Stiefel Healthcare Conference. Read more here: "

31 Oct

"@Epicbiotech partners with @KitePharma to extend the potential application of Epic’s platform for cancer treatment. Epic’s approach is promising for in vivo medicines and may enable next-generation cell therapies #epigenetics #CellTherapy #Cancer "